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Abstract
Background: Breast cancer is the most deadly malignancy in Mexican women. Although treatment has improved, it
may significantly affect bone mineral status in those who receive it. The aim of this study was to assess the impact of
cancer treatment on bone mineral density (BMD) and bone mineral content (BMC), in patients with breast cancer and
explore the interaction of menopausal status and clinical stage with cancer treatment on such changes.
Methods: A quasi-experimental design was applied with measurements before and after a chemotherapy treatment in
40 patients with primary diagnosis of invasive breast cancer. BMD and body composition measurements were taken by
dual X-ray absorptiometry (DXA) and changes in these variables due to therapy were analyzed using mixed regression
for repeated measurements.
Results: Significant loss was found in femoral neck and L2-L4 BMD (p < 0.001). Patients diagnosed with osteopenia or
osteoporosis received calcium+ vitamin D supplementation (600 mg/200 IU day). It showed a protective effect in the
decrease of femoral neck BMD and total BMC. BMD loss in both femoral neck and L2-L4 BMD was higher in
premenopausal women: 0.023 g/cm2 in femoral neck and 0.063 g/cm2 in L2-L4 (p < 0.001), while in postmenopausal
women BMD loss was 0.015 g/cm2 in femoral neck and 0.035 g/cm2 in L2-L4 (p = 0.021 and p = 0.001 respectively).
Change in lumbar spine BMD was prominent in premenopausal women with advanced clinical stage (IIB, IIIA, IIIB):
0.066 g/cm2 (p = 0.003).
Conclusion: The antineoplastic breast cancer treatment with chemotherapy had a negative impact on BMD, in
premenopausal women overall, although a differential effect was found according to clinical stage and calcium
supplementation status.
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Background
Breast cancer is considered the neoplasm with the highest
incidence and mortality rate in women worldwide. One
million seven hundred thousand new cases were recorded
in 2012, whereby is the second most common cancer
overall and ranks fifth cause of death (522000 deaths) [1].
Although the incidence of breast cancer in Latin
America is lower than those in the United States and the
European Union, the mortality proportion regarding in
those with the disease is high (>30 %), while in Mexico
is almost 40 %. Disparities in results are mainly
explained by the high prevalence of women diagnosed in
advanced stages. For example, 60 % of breast cancer
diagnoses are in early stages in the United States and
10 % in Mexico. This explains the most adverse side-
effects of the disease and anticancer treatment in those
with more advanced stages [2, 3].
During breast cancer, bone tissue is one of the most
affected, mainly by ovarian failure, secondary to chemo-
therapy. The role of estrogens in bone metabolism is
important as they stimulate bone formation by promoting
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osteoprotegerin production (bone formation induction
factor), regulating the synthesis of active cytokines in the
skeleton (promoted in part by the neoplasm itself ) and by
apoptosis inhibition of osteoblasts and osteocytes. Thus,
estrogen deficiency reduces osteoprotegerin production
which causes uncontrolled activity of osteoclasts increas-
ing bone resorption [4, 5].
Some studies have reported differential effects in treat-
ment response and survival, due to different body weight
and its distribution by ethnicity [6, 7]. Given the fact that
the Mexican population is genetically diverse, along with
the knowledge that environmental and demographic fac-
tors may also affect susceptibility to treatment, the objec-
tives of this study was to evaluate the impact of initial
anticancer therapy on bone mineral status in Mexican
women, by estimating the change in BMD in the femoral
neck, lumbar spine (L2-L4) and total BMC. An additional
objective was to evaluate the differential effect due to the
clinical stage and menopausal status on BMC and BMD.
Methods
The design is based on a quasi-experimental prospective
follow-up study of women with primary diagnosis of
invasive breast cancer who attended at the State Center
of Oncology (CEO from the acronym in Spanish) in
Hermosillo, Sonora, to begin the anticancer treatment.
The initial six-months of chemotherapy treatment was
assay. Women were invited if they showed no metastasis
or other diseases which affected their body composition
such as hypo and hyperthyroidism, fractures and/or dis-
abling injuries or those who had received chemotherapy
in the past. Patients were also excluded from the analysis
if they developed metastasis during the study course
and/or discontinued their treatment.
The protocol was approved by the Research Ethics
Committee of the CEO and Ethics Committee of the
Research Center for Food and Development (CIAD from
the acronym in Spanish). The recruited volunteers were
requested to sign an informed consent form. Informa-
tion on clinical stage, treatment schedule, menopausal
status (menstruation absence for over a year before
treatment), socioeconomic status (determined by the so-
cial work department of the hospital in terms of monthly
income, housing characteristics and access to basic ser-
vices, etc.) and demographic data were taken from the
clinical records of the participants at CEO with their
previous permission. Anthropometric, body composition
and BMD measurements were analyzed at CIAD
facilities.
Body composition and BMD were determined using a
dual X-ray absorptiometry (DXA-MD + Lunar Co.,
Madison, WI). Precision of that measures was Coeffi-
cient Variation (CV) <2 %. Three measurements (scans)
were obtained, one for the whole body to assess the
body composition and two in the lumbar spine (L2-L4)
and femoral neck to determine the BMD. The results of
body composition were reported in kilograms and BMD
in g/cm2. All measurements were performed by trained
and certificated technical staff before and after 6 months
of receiving antineoplastic therapy. Women with diagnosed
osteopenia or osteoporosis at baseline (n = 10) received a
prescription of calcium and vitamin D3 supplementation
(600 mg/200 IU day).
A total of 57 women were recruited from August 2007
to January 2008 (24 women) and from February to August
2009 (33 women). Three women dropped out the treat-
ment and 14 more were excluded from the study due to
metastases development during the tracking period; there-
fore, 40 patients were included in analyses.
Statistical analysis
All analyzes were performed with NCSS software version
7.03 (2007). A paired t-test was applied to analyze the
changes of the study parameters before and after treat-
ment. Normal distribution of the quantitative variables
was evaluated using histograms; all response variables
exhibit Gaussian distribution. To evaluate the treatment
related changes of total BMC, BMD on femoral neck
and L2-L4, separate mixed regression models for
repeated measures were used. Interaction terms of
hypothesized variable (treatment) with menopausal sta-
tus (pre or post), calcium supplementation (yes or no)
and clinical stage phase were considered at p ≤ 0.05.
When a significant interaction was found, stratified ana-
lyses were conducted. The clinical stage was analyzed as
a dichotomous variable due to the small number of sub-
jects in some stages. Stages I and IIA in one category
and stages IIB, IIIA and IIIB in a second one. Statistical
significance was considered at p ≤ 0.05.
Results
The patients age distribution was 32 to 61 years; 19 were
premenopausal and 21 postmenopausal. The average age
of menarche was 12 years. Five patients were nulliparous,
28 reported using oral contraceptives (>3 years), 6
recognized to be regular smokers (daily) at the diag-
nostic time and 7 accepted had consumed alcohol
occasionally (>1 time/week). Regarding education status,
11 women were enrolled beyond the basic level (high
school or technical degree). Regarding socioeconomic sta-
tus, 62.5 % were in low and 37.5 % in medium or high.
Five women were found in the stage I, 12 in IIA, 8 in
IIB, 9 in IIIA and 6 in IIIB (Classification TNM) [8]. All
patients received chemotherapy. Prescribed schedules
were FAC (5-Fluorouracil, Adriamycin, Cyclophospha-
mide), FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide)
or DAC (Docetaxel, Adriamycin, Cyclophosphamide). Of
the premenopausal patients 68 % become amenorrheic.
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Radiotherapy was additionally administered to 25 patients
and 7 were eligible for monoclonal antibodies treatment
(Trastuzumab); one of them not receive it for cardiac
issues. The clinical pathological characteristics and chemo-
therapy schemes distribution describes at Table 1.
Table 2 displays t-score of BMD distribution on pre-
menopausal and postmenopausal patients before and
after to receive antineoplastic treatment at femoral neck
and lumbar spine (L2-L4).
Table 3 shows parameters from the unadjusted ana-
lysis. Significant loss was observed in femoral neck and
L2-L4 BMD (p < 0.001). In BMC the change did not
reach statistical significance (p = 0.066).
A protective effect in the reduction of BMD at femoral
neck and total BMC due calcium supplementation was
found. In women supplemented there was no significant
decrease in femoral neck BMD or total BMC; but in
L2-L4 BMD which was significant (p = 0.003) despite
calcium+ vitamin D supplementation. Conversely, women
who did not receive calcium supplement, showed signifi-
cantly loss in femoral neck BMD, L2-L4 BMD and total
BMC (p < 0.001, p < 0.001 and p = 0.039) (Table 4).
There was also interaction between treatment effect
vs. menopausal status and vs. clinical stage (p < 0.05).
Consequently, all the analyses were completed in the
stratus of the interaction variables (Table 5). BMD loss
was significant in premenopausal and postmenopausal
women: −0.023 g/cm2 in femoral neck and −0.063 g/cm2
in L2-L4 (p < 0.001) in premenopausal women and
−0.015 g/cm2 in femoral neck (p = 0.021) and −0.035 g/cm2
in L2-L4 (p = 0.001) in postmenopausal. In premenopausal
patients decrease in L2-L4 BMD was directly related with
clinical stage: −0.059 g/cm2 on stage I, IIA (p = 0.006) and
−0.066 g/cm2 on stage IIB, IIIA, IIIB (p = 0.003). However,
in femoral neck, a reverse pattern was observed, where
BMD was −0.030 g/cm2 on stage I, IIA (p = 0.004) and
−0.017 g/cm2 on stage IIB, IIIA, IIIB (p = 0.007). Also this
trend remained between postmenopausal women, with sig-
nificant changes in stages I, IIA (p = 0.037 for femoral neck
and p < 0.001 for L2-L4).
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Invasive ductal carcinoma 18 19




Molecular subtypes (n = 28)a
Luminal A (RE+, RP+/-, HER2neu-) 1 3
Luminal B (RE+, RP+/-, HER2neu+) 4 5
HER2 (RE-, RP+/-, HER2+) 5 2


















Data in table are number of cases
aBecause patient recruitment started in 2007 and immunohistochemistry
determination of hormone receptors was instituted as part of the routine
battery of tests in 2008, not all underwent such a test
bNational Comprehensive Cancer Network (NCCN) Clinical guidelines
Table 2 Bone Mineral Density (BMD) T-scorea distribution and
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Data in table are number of cases
aWHO cut-off points. T-score is defined as BMD Standard Deviations (SD)
respect to 20–39 years old health population of same gender
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Discussion
Estrogen activity is linked to bone metabolism and some
chemotherapeutic agents such as cyclophosphamide
which is related with bone resorption because of ovarian
failure in premenopausal women related with this agent
[9, 10]. Although almost all volunteers showed a signifi-
cant loss in BMD, the impact was greater in premeno-
pausal women. Furthermore, the decrease in BMD is
higher than that reported by other authors during the
same post-diagnosis period (6 months): For example,
Shapiro et al.[9] reported 4 % lumbar spine BMD loss, in
the present study it was similar (almost 5 %). Other
studies reported comparable decline over a period of
two years [11, 12].
In postmenopausal patients, BMD change was −3.08 %.
Powles et al. [13] in a similar group of women, found that
the change in the lumbar spine BMD was only −0.37 %.
Since there is lack of information in the literature about
the magnitude of these changes in Mexican population
under an internationally standardized chemotherapy regi-
men [14, 15], we believe that perhaps other causes such as
genetic factors could be involved and can explain the
differential effect found in this study with respect to
others. Other studies have found that body composition
differs significantly between Hispanic and Caucasian
breast cancer female patients, however, neither group of
countries have established guidelines for the administra-
tion of antineoplastic drugs based on body composition,
in which case toxicity could be different for these groups
[16]. Since the effective concentration of these antineoplas-
tic drugs is affected by the amount of lean tissue [17, 18], it
is believed that this can be a key element to elucidate
the reason for the differences between the magnitude
of the changes on BMD found by others researchers
and the present study . The body antineoplastic con-
centration reached could also affect changes in body
weight and body composition components such as
BMD, fat mass, and fat free mass. However, other
factors such as the diet may be involved.
Some patients started treatment with osteopenia, and
calcium was part of their treatment. It appears that
calcium showed a significant protective effect on the
femur, but not on the lumbar spine. The explanation to
the lower BMD loss on femoral neck than lumbar spine
in both groups of women (calcium supplemented and
no-supplemented) may be the same. The proportion of
trabecular-cortical tissue and bone turnover rate are dif-
ferent in each skeletal region. The pathophysiology of
osteoporosis [19, 20] indicates that about 25 % of
trabecular bone (cancellous) is replaced every year, while
cortical bone (laminar) is replaced at a level of 3 %. This
is the reason why bone resorption degree is calculated
using BMD as a reference at the proximal femur (neck,
trochanter) and spine. Both sites contain high propor-
tion of cancellous tissue. Although these points have a
high content of trabecular bone compared to the rest of
the skeletal system, there is an important difference
in their composition. The fact that proximal femur
has 30–50 % of trabecular tissue whereas the lumbar
spine has 85 % explains why the lumbar spine is
more susceptible to the effect due to decreased estro-
gen level, so that bone tissue resorption at L2-L4





Δb pc Confidence Interval
95 %
BMD femoral neck (g/cm2) 1.02 ± 0.1 1.001 ± 0.1 −0.018 <0.001 (−0.026, −0.011)
BMD L2-L4 (g/cm2) 1.19 ± 0.2 1.15 ± 0.1 −0.048 <0.001 (−0.063, −0.033)
BMC (kg) 2.46 ± 0.34 2.43 ± 0.34 −0.032 0.066 (−0.065, 0.002)
BMDBone Mineral Density, BMC Bone Mineral Content
aMean ± SD
bΔ =measurement 2- measurement 1
cpaired t test
Table 4 Antineoplastic treatment effect on BMD and BMC based on oral calcium and vitamin D3 supplementation in breast cancer
patients (n = 40)
Parameter No calcium supplement (n = 30) Calcium supplement (n = 10)b
βa p Confidence Interval
95 %
βa p Confidence Interval
95 %
BMD femoral neck (g/cm2) −0.03 <0.001 (−0.036, −0.024) 0.006 0.344 (−0.007, 0.018)
BMD L2-L4 (g/cm2) −0.055 <0.001 (−0.076, −0.035) −0.033 0.003 (−0.052, −0.013)
BMC (kg) −0.047 0.039 (−0.092, −0.003) <0.001 0.987 (−0,052, 0.052)
BMD Bone Mineral Density, BMC Bone Mineral Content
aDetermined by mixed model regression for repeated measures. Calcium supplement and treatment interaction (p ≤ 0.05)
bCalcium and vitamin D3 supplementation (600 mg/200 IU day)
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resulted exacerbated. There is a greater release of
calcium into the bloodstream, which can maintain
parathyroid hormone (PTH) levels marginally low;
preventing activation and mobilization of enough vita-
min D on lumbar spine tissue to stimulate the
calcium bond. On the other hand, the femoral neck
bone turnover rate is lower and calcium supplied
along with activation and mobilization of vitamin D
with that level of PTH, is enough to raise the rate of
mineralization at the newly remodeled tissue.
A recent finding indicates that the involvement of
estrogens and its protective effect on trabecular tissue
metabolism is much higher than that in cortical tissue,
which could explain the higher susceptibility of cancel-
lous tissue to ovarian ablation, regardless of differences
in the rate of bone turnover between these tissues [21].
In addition to primary chemotherapeutic treatment
scheme, which contributes to bone resorption, breast
cancer patients received anti-estrogen therapy for a five-
year period. These drugs also favored the decrease in
BMD. Confavreux et al. [22] found that the patients who
underwent treatment with anastrozole had a decrease of
3.3 % in lumbar spine BMD and 2.8 % in femoral neck
in a one year period. Some investigations have published
similar effects as those of Letrozole, Tamoxifen and Exe-
mestane treatments [23–25].
Another consideration in decreasing BMD is the
increase in body weight in patients. As previously re-
ported [26], this patients group decreased lean mass,
while premenopausal women increased body weight and
adipose tissue. Since one of the mechanisms that stimu-
lates the bone remodeling is the body calcium demand,
it appears that the higher increase of body mass the
greater the rate of calcium mobilization from bone
matrix, combined with poor bone remodeling by estro-
gen loss which can help control osteoclastic activity [20].
However, the fact that fat tissue showed higher increase
than lean tissue, could result in increased toxicity due to
antineoplastic drugs, because they can have a greater
effect since the dosage thereof is calculated according to
total body weight but its real concentration in the body
is affected for the lean tissue proportion. This could be a
reason to suggest the evaluation of sarcopenia status in
patients with cancer as well as chemotherapy dose
adjustments [17, 18].
An additional finding is the clinical stage effect on
BMD. In the initial chemotherapy scheme there are no
important differences in the antineoplastic doses and
their combinations between clinical stages that could
result in a different effect on estrogen concentration in
the 6-month-follow-up period. Variations in treatment
are prescribed depending on factors such as the type of
carcinoma (ductal, lobular, etc.), molecular subtype and
the age of the patients [15]. Patients in medium (IIB) or
advanced clinical stages (IIIA, IIIB) are the most affected
in regards to BMD, which could be explained by the
tumor’s increased production of catabolic cytokines as
well as by the body’s induced response [27, 28]. There is
also the effect mediated by IL-1, IL-6, IFNγ and TNFα,
that increases the invasiveness of the tumor on bone
tissue. These cytokines also contribute to the loss of lean
tissue in cancer patients with cachexia [29]. The loss of
lean tissue can be masked by increased body fat in breast
cancer patients [30].
The evaluation of BMD is not a routinely part of the
treatment in cancer patients, even considering the harmful
effects of anticancer and anti-estrogen on bone matrix.
Breast cancer women may benefit from a proper diagnosis,
Table 5 Antineoplastic treatment effect on BMD and BMC depending on menopausal status and clinical stage in breast cancer
patients (n = 40)
Parameter Premenopause (n = 19) Postmenopause (n = 21)
βa p Confidence Interval
95 %
βa p Confidence Interval
95 %
BMD femoral neck (g/cm2)b All −0.023 <0.001 (−0.032, −0.013) −0.015 0.021 (−0.027, −0.002)
Clinical stage I, IIA (n = 17)c −0.030 0.004 (−0.047, −0.013) −0.018 0.037 (−0.034, −0.001)
Clinical stage IIB, IIIA, IIIB (n = 23)c −0.017 0.007 (−0.029, −0.006) −0.0123 0.198 (−0.032, 0.008)
BMD L2-L4 (g/cm2)b All −0.063 <0.001 (−0.086, −0.039) −0.035 0.001 (−0.054, −0.016)
Clinical stage I, IIA (n = 17)c −0.059 0.006 (−0.095, −0.023) −0.043 <0.001 (−0.059, −0.026)
Clinical stage IIB, IIIA, IIIB (n = 23)c −0.066 0.003 (−0.102, −0.029) −0.029 0.088 (−0.062, 0.005)
BMC (kg)b All −0.027 0.29 (−0.078, 0.025) −0.036 0.140 (−0.085, 0.013)
Clinical stage I, IIA (n = 17)c −0.019 0.66 (−0.118, 0.079) −0.005 0.895 (−0.088, 0.078)
Clinical stage IIB, IIIA, IIIB (n = 23)c −0.032 0.33 (−0.103, 0.038) −0.059 0.078 (−0.126, 0.008)
BMD Bone Mineral Density, BMC Bone Mineral Content
aDetermined by mixed model regression for repeated measures
bMenopausal status and treatment interaction (p ≤ 0.05)
cMenopausal status and clinical stage interaction (p ≤ 0.05)
Monroy-Cisneros et al. BMC Cancer  (2016) 16:860 Page 5 of 7
plus the fact that they could also be given antirresorptive
drugs with no additional cost to the patient that is already
covered by the public government health programs. One
might speculate that loss in BMD is not so relevant when
considering the cost-benefit ratio of cancer treatment, in
short term. In our study we found 4.97 % of BMD loss at
the lumbar spine in six months. Saarto et al. [12] evaluated
a group of patients and after two years found a similar de-
crease of BMD; after ten years, 23 % of them developed
osteoporosis [31].
Health institutions worldwide should implement the
evaluation of BMD in patients with breast cancer as part
of the treatment regimen as suggested by the American
Society of Clinical Oncology (ASCO) [32]. In addition,
antiresorptive therapies could prevent bone metastasis
[33]. Due to the alert issued in 2011 by the Food and
Drug Administration (FDA) regarding the kidney dam-
age in some cases, the ASCO recommended the limited
use of bisphosphonates to the patients with bone metas-
tases, restricting their prescription in patients with
osteopenia or osteoporosis with no evidence of bone
destruction diagnosed by X-ray Computed Tomography
(CT) or Magnetic Resonance Imaging (MRI) [34]. How-
ever, since the high loss in BMD found in this study, it is
suggested that the treatment could be implemented in
patients with osteopenia and osteoporosis at baseline;
while monitoring renal function, as routinely done for
patients receiving cisplatin in chemotherapy scheme
[35]. This strategy may reduce long-term costs, would
impact positively on the quality of life and survival of
these women.
A few limitations should be mentioned. Due to the
nature of the study design and the fact that the chemo-
therapy treatment scheme was standardized, it is not
possible isolate completely the effect thereof on the mea-
sured parameters considered. For this reason, it is un-
known the influence of the tumor on BMD changes and
its induced catabolic body response. Furthermore, the
protective effect of calcium supplementation on
demineralization in the femoral neck must be inter-
preted with caution since supplemented patients who
initiated treatment had osteopenia. It is considered that
women who begin the chemotherapy scheme with
normal BMD calcium supplementation could not have
the same effect. One more limitation was the small sam-
ple size in this study which confines its generalizability.
Therefore, results need to be replicated in larger studies.
Conclusions
This study showed evidence of a significant reduction of
BMD in both femoral neck and L2-L4. Due to treatment
and menopausal status interaction, bone resorption was
higher in premenopausal patients. Also, calcium supple-
mentation exerted a protective effect by reducing the
loss of total BMC and femoral neck BMD. The treat-
ment and clinical stage interaction on L2-L4 BMD loss
suggested that the bone resorption could be due not
only to the antineoplastic drugs, but also to the disease
itself, which could have had an effect even before clinical
signs such as the bone metastasis and cachexia appeared.
However, further studies focused on tumor response at
the initial phase of treatment are required to elucidate
the extent of malignancy per se.
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